简介：Epithelialovariancancerisprimarilyadiseaseofolderwomen.Advancedageisriskfactorfordecreasedsurvival.Optimalsurgeryandthesafeandeffectiveadministrationofchemotherapyareessentialforprolongedprogression-freeandoverallsurvival(OS).Inthisarticle,theavailableregimensinboththeprimarytreatmentandrelapsedsettingarereviewed.

简介：Objective:Theexpressionoftumorbiomarkersmaychangeafterchemotherapy.However,whethersecretedproteinacidicandrichincysteine(SPARC)expressionchangesafterchemotherapyingastriccancer(GC)isunclear.ThisstudyinvestigatedtheinfluenceofchemotherapyonSPARCexpressioninGC.Methods:ImmunohistochemistrywasusedtoanalyzeSPARCexpressionin132GCcases(including54caseswithpreoperativechemotherapyand78caseswithoutpreoperativechemotherapy).SPARCexpressionofpostoperativespecimenswithandwithoutpreoperativechemotherapywasassessedtoanalyzetheinfluenceofchemotherapyonSPARCexpression.Results:SPARCwashighlyexpressedinGCcomparedwiththedesmoplasticstromasurroundingtumorcellsandnoncanceroustissues.HighSPARCexpressionwascorrelatedwithinvasiondepth,lymphnode,andTNMstage.Afterchemotherapy,alowerproportionofhighSPARCexpressionwasobservedinpatientswithpreoperativechemotherapythaninthecontrols.For54patientswithpreoperativechemotherapy,grosstype,histology,depthofinvasion,lymphnode,TNMstage,andSPARCexpressionwererelatedtooverallsurvival.Furthermultivariateanalysisshowedthatlymphnode,histology,andSPARCexpressionafterchemotherapywereindependentprognosticfactors.Conclusion:SPARCexpressionmaychangeafterchemotherapyinGC.SPARCexpressionshouldbereassessedforpatientswithGCafterchemotherapy.

简介：客观化疗是治疗乳癌的一个有效工具，并且癌症特定的replicative侵入人体气管粘膜的病菌也是最近的年里的一个有希望的反肿瘤代理人。我们表明那个CNHK300罐头的调查目的调停选择的反肿瘤功效并且在HER-2过去表示的乳癌上与化疗生产协同的细胞毒性。我们由把E1A基因放在人的hTERT倡导者的控制下面设计了telomerase依赖的replicative侵入人体气管粘膜的病菌CNHK300的方法。由E1A表示的分析，我们在telomerase积极的乳癌房间然而并非在正常成纤维细胞房间在侵入人体气管粘膜的病菌染色体和E1A的选择表示证明了hTERT倡导者的忠实。由增长测试，我们进一步在正常成纤维细胞房间与显然稀释的增长在乳癌房间显示出CNHK300的有效复制。最后，我们由那个CNHK300病毒引起了有势力细胞溶解并且在正常细胞上与稀释细胞毒性在乳癌房间与化疗生产了协同的细胞毒性的MTT方法示威了。在这个病毒的结果，E1A基因成功地被放在人的hTERT倡导者的控制下面。象野类型的侵入人体气管粘膜的病菌一样高效地复制并且引起了集中的房间在HER-2过去表示的乳癌房间在试管内杀死的CNHK300病毒。相反，telomerase否定的正常成纤维细胞房间，没表示hTERT活动，不能支持CNHK300复制。有paclitaxel的CNHK300的联合治疗在癌症房间上改进了细胞毒性。我们结束那CNHK300的结论能生产选择的反肿瘤功效并且在表示乳癌上在HER-2上提高化疗的在试管内反应。

简介：Objective:Survivalandtreatmentofpatientswithmicroinvasivebreastcancer(MIBC)remaincontroversial.Inthispaper,weevaluatedwhetheradjuvantchemotherapyisnecessaryforpatientswithMIBCtoidentifyriskfactorsinfluencingitsprognosisanddecidetheindicationforadjuvantchemotherapy.Methods:Inthisretrospectivestudy,108patientswithMIBCwererecruitedaccordingtoseventheditionofthestagingmanualoftheAmericanJointCommitteeonCancer(AJCC).Thesubjectsweredividedintochemotherapyandnon-chemotherapygroups.Wecomparedthe5-yeardisease-freesurvival(DFS)andoverallsurvival(OS)ratesbetweengroups.Furthermore,weanalyzedthefactorsrelatedtoprognosisforpatientswithMIBCusingunivariateandmultivariateanalyses.Wealsoevaluatedtheimpactofadjuvantchemotherapyontheprognosticfactorsbysubgroupanalysisaftermedianfollow-uptimeof33months(13-104months).Results:The5-yearDFSandOSratesforthechemotherapygroupwere93.7%and97.5%,whereasthoseforthenonchemotherapygroupwere89.7%and100%.Resultsindicatethat5-yearDFSwassuperior,butOSwasinferior,intheformergroupcomparedwiththelattergroup.However,nostatisticalsignificancewasobservedinthe5-yearDFS(P=0.223)orOS(P=0.530)rateofthetwogroups.Mostrelevantpoor-prognosticfactorswereKi-67overexpressionandnegativehormonalreceptors.Cumulativesurvivalwas98.2%vs.86.5%betweenlowKi-67(≤20%)andhighKi-67(>20%).ThehazardratioofpatientswithhighKi-67was16.585[95%confidenceinterval(CI),1.969-139.724;P=0.010].Meanwhile,ER(-)/PR(-)patientswithMIBChadcumulativesurvivalof79.3%comparedwith97.5%forER(+)orPR(+)patientswithMIBC.ThehazardratioforER(-)/PR(-)patientswithMIBCwas19.149(95%CI,3.702-99.057;P<0.001).SubgroupanalysisshowedthatchemotherapycouldimprovetheoutcomesofER(-)/PR(-)patients(P=0.014),butnotthosewhooverexpressKi-67(P=0.105).Conclusions:PatientswithMIBCwhooverexpressKi-67and

简介：摘要：在中介或先进的胰腺的头癌上改进辩解的效果。方法：手术与intermediated或先进的胰腺的头癌在26个病人被动。在癌上与一根电子横梁与intraoperative放射疗法相结合的Cholecystojejunostomy或choledochojejunostomy从1996年5月被执行到1998年5月。同时，多功能的可植入的药交货系统的导管为手术后的灌注化疗经由胃与十二指肠的动脉被插入。结果：327月后续调查建议肿瘤在治疗的功课以后在不同的度缩小了。所有病人疼痛被减轻。6月、12月、24月的幸存率是100%，93.9%和20%分别地。5个死了的病人的平均幸存时间是17.8个月。结论：这操作是很完成与中介或先进的胰腺的头癌延长病人的生活。

简介：Autoimmunehepatitis(AIH)hasrarelybeendescribedasanautoimmuneparaneoplasticsyndromeofthymoma.ThiscaseistheseventhcaseofAIHrevealedbycholestasisfewyearsafterthediagnosisofthymomaandthefirstcasetreatedwithchemotherapyalone.Wereportinthispaperanewapproachtothisrareseverecondition.A29year-oldmanpresentedwithchestpainanddyspneawithahistoryofthymomasurgicallyremoved4yearsago.CTscanshowedtherecurrenceofananteriormediastinalmass.Biologyshowedelevatedliverenzymesandprofoundcholestasis.Nosignofviralortoxichepatitisorbileductabnormalitieswereobserved.Autoimmuneantibodies,exceptfortheanti-nuclearantibody,werenegative.LiverbiopsyshowedactivechronicAIH.ThepatientwasdiagnosedwithrecurrentthymomawithAIHandunderwent6cyclesofchemotherapy.Acompleteresponseonthymomaandcholestasiswasobtainedafter10monthsoffollow-up.SteroidsandimmunosuppressorsarethestandardtreatmentforAIH.Theeffectofchemotherapyasaspecifictreatmentofthisparaneoplasticsyndromeneedstobeconsidered.

简介：Advancedgastriccancer(GC)hasbeenrecognizedaslethaldiseasewhenperitonealmetastases(PM)occurred.ThereisnostandardtreatmentforadvancedGCwithPM.Until1980s,thetherapeuticarenaforthesepatientshadremainedstagnant,withnotherapeuticapproachhavingshownasurvivalgaininGCwithPM.However,cytoreductivesurgery(CRS)withperitonectomyproceduresandintraperitonealchemotherapy(IPC)promisingnewcombinedtherapeuticapproachtoachievediseasecontrolforGCwithPM.TherecentpublicationschangedtheGCwithPMtreatmentlandscapebyprovidinganevidencethatCRSandIPCledtoprolongationinoverallsurvival(OS).ThisreviewwillprovideanoverviewoftheevolvingroleofCRSandIPCinthemanagementofadvancedGCwithPMinthecurrentera.

简介：Objective:Chemotherapyisthestandardtreatmentforsmall-celllungcancer(SCLC),andleukopeniaisacommonsideeffect.Thisstudyassesseswhetherchemotherapy-inducedleukopeniaisapredictorofefficacyandwhetheritisassociatedwiththesurvivalofSCLCpatients.Methods:Aretrospectiveanalysiswasconductedondatafrom445patientswithSCLCwhoreceivedstandardchemotherapyfor4to10cycles.TheWorldHealthOrganizationgradingsystemclassifiesleukopeniaduringchemotherapyasfollows:absent(grade0),mild(grades1and2),orsevere(grades3and4).Theprimaryendpointisoverallsurvival(OS).Results:Theassociationbetweenchemotherapy-inducedleukopeniaandOSwasassessed.AccordingtoamultivariateCoxmodelwithtime-varyingcovariates,thehazardratioofdeathwassignificantlyloweramongpatientswithmildleukopeniathanamongpatientswithsevereleukopeniaat0.687(0.506to0.943)and1.414(1.147to1.744),respectively.Themediansurvivalwas13months(95%CI:11to15months)forpatientswhodidnotexperienceleukopenia,17months(95%CI:14to18months)forthosewithmildleukopenia,and14months(95%CI:13to16months)forthosewithsevereleukopenia(absentvs.mildvs.severeleukopenia,P=0.047).Conclusion:LeukopeniaduringchemotherapyisassociatedwiththesurvivalofSCLCpatients.Mildleukopeniaisstronglyassociatedwithlongersurvivaltime.

简介：

简介：对在中间风险、高风险的子宫内膜的癌症的辅助治疗的实践和结果的现在的模式客观。有从1999～2006的中间风险、高风险的子宫内膜的癌症的224个女人上的方法回顾的数据被考察。所有病人经历了外科的阶段。辅助治疗的模式，加化疗由骨盆的放射疗法，化疗，和放射疗法组成，被估计。3年、5年的疾病特定的幸存(决策支持系统)率用Kaplan-Meier方法被计算。结果处于5年的决策支持系统率的差别在辅助的组和非辅助的组之间是统计上重要的(80.65%对63.80%，P=0.040)。在经历了辅助治疗的110个高风险的病人，两5年的决策支持系统率和周期性的率独自与放射疗法相比在联合放射疗法和化疗组是显著地不同的，化疗独自组织(决策支持系统率，P=0.049；周期性的率，P=0.047)。在经历了辅助治疗的83个中间风险的女人，在联合放射疗法之中处于5年的决策支持系统率和复发率没有重要差别，化疗，独自一个的放射疗法和化疗独自组织(决策支持系统率，P=0.776；周期性的率，P=0.937)。加化疗的结论辅助放射疗法在高风险的子宫内膜的癌症病人独自与独自一个的放射疗法和化疗相比与更高5年的决策支持系统率和更低的复发率被联系。有中间风险的子宫内膜的癌症的病人可能不是可能的得益于辅助联合放射疗法和化疗。

简介：A60-year-oldwomanwithsquamouscellcarcinomaintherightlungwassuccessfullytreatedwithfourcyclesofcombinationchemotherapyaftersurgery,andcompleteremissionwasachieved.However,thepatientdevelopedmyelodysplasticsyndrome(MDS)RAEB-2withmyelofibrosisafterremission,possiblybecauseofchemotherapyorDNAmethylation.Thepatientrespondedwelltodacitabine(Dacogen),suggestingthatDNAhypomethylationagentscanbeapromisingtherapytoretardtheprogressionofasecondtumororcarcinoma.

简介：比较在主要debulking外科(PDS)和neoadjuvant化疗之间的幸存和perioperative病态的目的在与先进上皮的卵巢的癌症(EOC)对待病人由间隔debulking外科(NAC/IDS)列在后面。我们回顾地与阶段IIIC或IVEOC考察了67个病人的方法从2006年1月在北京大学癌症医院对待到2009年6月。在那里，37和30个病人分别地经历了PDS和NAC/标志。结果在全面幸存(OS)或没有前进的幸存(PFS)的差别都没在NAC/IDS组和PDS组之间被观察(OS：41.2对39.1个月，P=0.23；PFS：27.1对24.3个月，P=0.37)。最佳的debulking率在NAC/IDS组是60%，它在PDS组(32.4%)(P=0.024)比那显著地高。NAC/IDS组显著地有比PDS的肠的功能的估计的血损失和输送，更低的nasogastricintubation率，和更早的移动和恢复组织的更少的intraoperative(P<0.05)。结论NAC/IDS不比PDS侵略，并且关于最佳的cytoreduction率，intraoperative血损失，和手术后的恢复提供优点，没有显著地损害与在对待有阶段IIIC或IVEOC的病人的PDS相比的幸存。因此，NAC/IDS可以是为EOC病人的一种珍贵治疗选择。

简介：FromJanuary1989toJuly1992,70patientsAcceptedforpublication.October23,1998CorrespondencetofXUGuang-chuan;DepartmentofOncology,TumorHospital,SunYat-SenUniversityofMedicalSciences,No.651,DongFengEastRoad,Guangzhou510060,China,Faxf(0086-20)-87761547;Phon...

简介：Sclerosing上皮状的纤维肉瘤(SEF)是纤维肉瘤的稀罕、糟糕定义的变体，但是对与穷人一起的化疗和进步通常感觉迟钝预后。我们报导irinotecanhydrochloride(CPT-11)的奇妙的效果在rescuing的化疗在几个治疗方法以后经历了复发的有从突现的状况的不正常的SEF的一个病人。CPT-11的小剂量予病人被以，与哪个，表面的质量(颈的淋巴节点)的尺寸逐渐地减少了在5天内由肉眼观察了。X射线和CT图象在肿瘤的尺寸证明了显著减小。CPT-11为这个好攻击的肉瘤的治疗是珍贵的。处于肉瘤压迫引起的紧急情况的状况，管理topoisomerase我禁止药的可容忍的小剂量能是一种有益的选择。

简介：

简介：客观试验性的证据建议胸的overexpression癌症特定的肿瘤suppressor蛋白质1(BRCA1)基因提高敏感到docetaxel和抵抗到cisplatin和ribonucleotidereductaseM1(RRM1)基因overexpression提高抵抗到gemcitabine。为了进一步检验BRCA1和RRM1mRNA的效果，在先进非小的房间肺癌症(NSCLC)在结果上铺平，我们执行了测试了那设定的治疗将授与的假设的这非使随机化的阶段II临床的审判在noncustomized上的改进结果治疗。

简介：Objective:Theaimofthisprospective,single-armphaseIItrialwastoconfirmthesafetyandefficacyofneoadjuvantchemotherapy(NAC)usingoxaliplatinpluscapecitabine(CapOX)forpatientswithoperablelocallyadvancedcoloncancer(CC).Methods:Patientswithcomputedtomography-definedT4orlymphnode-positiveCCswereenrolled.Afterradiologicalstaging,patientsweretreatedwithatleast2cyclesofNACconsistingof130mg/m2oxaliplatinond1,plus1,000mg/m2capecitabinetwicedailyfor14devery3weeks,followedbysurgery,andthenwiththerestcyclesofadjuvantchemotherapy.Radiologicalresponsewasevaluatedafter2cyclesofNAC.Tumorresponse,treatmenttoxicity,andsurgicalcomplicationswererecorded.Thepathologicalresponsetotherapywasevaluatedaccordingtothetumorregressiongrade(TRG)score.Theprimaryendpointwaspathologictumorresponse.ThistrialisregisteredinClinicalTrials.gov(No:NCT02415829).Results:Forty-sevenpatientswereenrolledinthestudy.Forty-twopatientscompletedtheplannedtreatments.Thetotalradiologicalresponseratewas68%(32/47),includingcompleteandpartialresponseratesof2%(1/47)and66%(31/47),respectively.Stablediseasewasobservedin32%(15/47)andprogressivediseasewasobservedinnone.Completepathologicresponse,majorregression,andatleastmoderateregressionwereachievedin1(2%),2(4%),and29(62%)patients,respectively.Fourpatientsdevelopedgrade3treatmenttoxicities.Onepatientwithwoundinfectionoccurredafteroperation(1/47,2%).Therewasnotreatment-relateddeath.Conclusions:OurresultssuggestthatNACwithCapOXisaneffectiveandsafetreatmentoptionforpatientswithlocallyadvancedCCs.

简介：在病人作为首要或第二线的治疗评估paclitaxel，cisplatin和5-FU(PCF)的联合政体的功效和毒性与的目的进展胃并且在中国的esophagogastric连接(EGJ)腺癌。病人与paclitaxel被对待的方法d1上的150mg/m2；fractionatedcisplatin15mg/m2和连续注入5-FU600mg/(m2朠楬污映扩楲汬牡????????????М

简介：Objective:Anti-angiogenicdrugsareanemergingtreatmentoptionagainstmalignanttumors.Theaimofthisstudywastodeterminewhethertheadditionofperioperativerh-endostatintochemotherapycouldimprovetheprobabilityofdistantmetastasis-freesurvival(DMFS)andoverallsurvival(OS)inpatientsnewlydiagnosedwithnon-metastaticconventionalosteosarcoma.Methods:Thiswasacontrollednon-randomizedclinicalstudythatincluded388patientswithoutclinicallydetectablemetastaticdiseaseenrolledfromJanuary2008toApril2012.Thecontroltreatmentgrouphad272patients;180weremaleand92,female,withamedianageof17years.Thetreatmentgrouphad58patients;36weremaleand22,female,withamedianageof16years.Thecontrolgroupreceivedpreoperativechemotherapyfollowedbysurgeryandpostoperativechemotherapy.Thetreatmentgroupreceived4cyclesofrh-endostatinperioperativelyinadditiontochemotherapyasperthecontrolgroup.Patientswerefollowedupfrom6-101monthswithamedianfollow-upperiodof50.2months.Results:The5-yearDMFSofthecontrolgroup(61%)wassignificantlylowerthanthatoftherh-endostatingroup(79%)(P=0.013).The5-yearOSofthecontrolgroup(74%)wassignificantlylowerthanthatoftherh-endostatintreatmentgroup(87%)(P=0.029).Nodifferenceinadversedrugreactionswasfoundbetweenthese2groups.Conclusions:Theadditionofperioperativerh-endostatintochemotherapycouldsignificantlyimprovetheDMFSandOSofpatientswithnon-metastaticosteosarcoma.

简介：